ECSP11010998A - Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundida - Google Patents
Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundidaInfo
- Publication number
- ECSP11010998A ECSP11010998A EC2011010998A ECSP11010998A ECSP11010998A EC SP11010998 A ECSP11010998 A EC SP11010998A EC 2011010998 A EC2011010998 A EC 2011010998A EC SP11010998 A ECSP11010998 A EC SP11010998A EC SP11010998 A ECSP11010998 A EC SP11010998A
- Authority
- EC
- Ecuador
- Prior art keywords
- alisquirene
- preparation
- extrusion granulation
- galenic formulation
- fused extrusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a formulaciones galénicas, en donde el ingrediente activo de alisquireno, de preferencia una sal de hemi-fumarato del mismo, solo o en combinación con otro ingrediente activo, se granula por fusión, y está presente en una cantidad de más del 20 por ciento en peso, basándose en el peso total de la forma de dosificación oral, así como a un proceso para la preparación de esta forma de dosificación oral sólida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9959508P | 2008-09-24 | 2008-09-24 | |
US16179909P | 2009-03-20 | 2009-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11010998A true ECSP11010998A (es) | 2011-06-30 |
Family
ID=41323516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011010998A ECSP11010998A (es) | 2008-09-24 | 2011-04-21 | Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundida |
Country Status (19)
Country | Link |
---|---|
US (1) | US20110177166A1 (es) |
EP (1) | EP2328562A1 (es) |
JP (1) | JP2012503665A (es) |
KR (1) | KR20110063684A (es) |
CN (1) | CN102164584A (es) |
AR (1) | AR073651A1 (es) |
AU (1) | AU2009296718A1 (es) |
BR (1) | BRPI0919077A2 (es) |
CA (1) | CA2736259A1 (es) |
CL (1) | CL2011000614A1 (es) |
CO (1) | CO6351712A2 (es) |
EC (1) | ECSP11010998A (es) |
MA (1) | MA32722B1 (es) |
MX (1) | MX2011003077A (es) |
PE (1) | PE20110925A1 (es) |
RU (1) | RU2011116122A (es) |
TW (1) | TW201016210A (es) |
WO (1) | WO2010036686A1 (es) |
ZA (1) | ZA201101686B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012520895A (ja) * | 2009-03-20 | 2012-09-10 | ノバルティス アーゲー | バルサルタンおよびアリスキレンの一定用量の組合せのガレヌス製剤 |
EP2382967A1 (de) * | 2010-04-21 | 2011-11-02 | ratiopharm GmbH | Aliskiren in Form einer festen Dispersion |
TWI657090B (zh) * | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
FR3055800B1 (fr) * | 2016-09-15 | 2020-06-26 | Unither Pharmaceuticals | Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
PE20060652A1 (es) * | 2004-08-27 | 2006-08-11 | Novartis Ag | Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion |
US20080075772A1 (en) * | 2006-04-13 | 2008-03-27 | Lawrence Solomon | Pharmaceutical compositions having novel scoring patterns and methods of using those compositions |
CN101594857B (zh) * | 2006-11-07 | 2012-10-31 | 诺瓦提斯公司 | 阿利吉仑半富马酸盐的晶形 |
EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
WO2009040427A1 (en) * | 2007-09-28 | 2009-04-02 | Novartis Ag | Galenical formulations of organic compounds |
US20100209480A1 (en) * | 2007-09-28 | 2010-08-19 | Ralf Altenburger | Galenical formulations of organic compounds |
EP2062874B1 (en) * | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
-
2009
- 2009-09-22 AR ARP090103629A patent/AR073651A1/es unknown
- 2009-09-23 TW TW098132133A patent/TW201016210A/zh unknown
- 2009-09-23 CN CN2009801373641A patent/CN102164584A/zh active Pending
- 2009-09-23 JP JP2011529177A patent/JP2012503665A/ja active Pending
- 2009-09-23 RU RU2011116122/15A patent/RU2011116122A/ru not_active Application Discontinuation
- 2009-09-23 CA CA2736259A patent/CA2736259A1/en not_active Abandoned
- 2009-09-23 EP EP09792885A patent/EP2328562A1/en not_active Withdrawn
- 2009-09-23 MX MX2011003077A patent/MX2011003077A/es not_active Application Discontinuation
- 2009-09-23 WO PCT/US2009/057993 patent/WO2010036686A1/en active Application Filing
- 2009-09-23 AU AU2009296718A patent/AU2009296718A1/en not_active Abandoned
- 2009-09-23 KR KR1020117009209A patent/KR20110063684A/ko not_active Application Discontinuation
- 2009-09-23 US US13/120,182 patent/US20110177166A1/en not_active Abandoned
- 2009-09-23 PE PE2011000667A patent/PE20110925A1/es not_active Application Discontinuation
- 2009-09-23 BR BRPI0919077A patent/BRPI0919077A2/pt not_active IP Right Cessation
-
2011
- 2011-03-04 ZA ZA2011/01686A patent/ZA201101686B/en unknown
- 2011-03-23 CL CL2011000614A patent/CL2011000614A1/es unknown
- 2011-03-25 CO CO11036970A patent/CO6351712A2/es not_active Application Discontinuation
- 2011-04-20 MA MA33785A patent/MA32722B1/fr unknown
- 2011-04-21 EC EC2011010998A patent/ECSP11010998A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN102164584A (zh) | 2011-08-24 |
EP2328562A1 (en) | 2011-06-08 |
RU2011116122A (ru) | 2012-10-27 |
CL2011000614A1 (es) | 2011-11-04 |
TW201016210A (en) | 2010-05-01 |
AR073651A1 (es) | 2010-11-24 |
MA32722B1 (fr) | 2011-10-02 |
WO2010036686A1 (en) | 2010-04-01 |
PE20110925A1 (es) | 2012-01-13 |
CA2736259A1 (en) | 2010-04-01 |
BRPI0919077A2 (pt) | 2015-12-15 |
CO6351712A2 (es) | 2011-12-20 |
MX2011003077A (es) | 2011-08-03 |
KR20110063684A (ko) | 2011-06-13 |
ZA201101686B (en) | 2012-01-25 |
AU2009296718A1 (en) | 2010-04-01 |
JP2012503665A (ja) | 2012-02-09 |
US20110177166A1 (en) | 2011-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014011841A2 (pt) | material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos | |
BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
CU24065B1 (es) | Forma de dosificación farmacéutica que comprende nifedipino y un antagonista de angiotensina ii | |
ECSP066715A (es) | ||
CL2007002485A1 (es) | Proceso para preparar una forma de dosificacion farmaceutica oral solida de leberacion extendida que comprende un agente aactivo y oxido de polietileno de peso molecular de al menos 1.000.000, que incluye un paso de curado sometiendola a la temperatura de reblandecimiento o fusion (al menos parcial) del oxido de polietileno. | |
HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
CR11285A (es) | Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihipropiridina y metodo para la prepacion de la misma | |
BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
CO6470803A2 (es) | Una formulacion novedosa de meloxicam | |
MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
CO6220902A2 (es) | Formulacion en polvo del valganciclovir | |
CR20120623A (es) | Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-Ona | |
TN2015000135A1 (en) | Modified release formulations for oprozomib | |
MY159492A (en) | Solid pharmaceutical formulation with delayed release | |
BR112012028788A2 (pt) | fabricação de grânulos sem ativos | |
ECSP11010998A (es) | Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundida | |
EA201270573A1 (ru) | Гранулированный в расплаве цинакальцет | |
GT201000064A (es) | Formulaciones galénicas de alisquireno | |
UY30798A1 (es) | Sales de timo depresores farmacéuticamente aceptables y procesos para su manufactura | |
MX2009005329A (es) | Composiciones farmaceuticas anticonvulsivas. | |
CO6460763A2 (es) | Métodos y formulaciones ectoparasiticidas |